↓ Skip to main content

Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Overview of attention for article published in Clinical Cancer Research, May 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
14 news outlets
blogs
1 blog
twitter
52 tweeters

Readers on

mendeley
4 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Published in
Clinical Cancer Research, May 2022
DOI 10.1158/1078-0432.ccr-22-0413
Pubmed ID
Authors

Mojun Zhu, Chunhua Chen, Nathan R. Foster, Christopher Hartley, Taofic Mounajjed, Marcela A. Salomao, Briant F. Fruth, Staci E. Beamer, Yohan Kim, Susan M. Harrington, Henry C. Pitot, Cristobal T. Sanhueza, Yening Feng, Joerg Herrmann, Robert R. McWilliams, Fabrice Lucien, Bing Q. Huang, Wen Wee Ma, Tanios S. Bekaii-Saab, Haidong Dong, Dennis Wigle, Daniel H. Ahn, Chris L. Hallemeier, Shanda Blackmon, Harry H. Yoon

Twitter Demographics

The data shown below were collected from the profiles of 52 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 1 25%
Unspecified 1 25%
Student > Postgraduate 1 25%
Unknown 1 25%
Readers by discipline Count As %
Medicine and Dentistry 2 50%
Unspecified 1 25%
Unknown 1 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 135. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2022.
All research outputs
#236,852
of 21,794,353 outputs
Outputs from Clinical Cancer Research
#93
of 12,337 outputs
Outputs of similar age
#6,290
of 340,759 outputs
Outputs of similar age from Clinical Cancer Research
#5
of 145 outputs
Altmetric has tracked 21,794,353 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,337 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,759 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 145 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.